SCHEDULE 13D/A: Medpace Holdings Insider August J. Troendle Increases Stake Through Option Exercises
Beneficial Ownership Update
August J. Troendle, a key reporting person for Medpace Holdings, Inc., has increased his beneficial ownership to 19.5% of common stock through recent option grants and exercises.
Summary
- This document is Amendment No. 22 to the Schedule 13D filing for Medpace Holdings, Inc. (the "Issuer").
- August J. Troendle beneficially owns 6,018,308 shares of Medpace Holdings, Inc. common stock, representing 19.5% of the class.
- Medpace Investors, LLC beneficially owns 4,733,019 shares, representing 15.3% of the common stock, with shared voting and dispositive power with August J. Troendle.
- On March 6, 2025, August J. Troendle was granted 73,443 options that vested immediately.
- On March 7, 2025, August J. Troendle exercised a total of 356,446 vested stock options.
- The exercised options included 37,417 shares at a strike price of $54.74, 234,259 shares at a strike price of $56.61, and 84,770 shares at a strike price of $107.93.
- No other transactions in the Issuer's Common Stock by the Reporting Persons have occurred within the last 60 days, except for those reported herein.
Sentiment
Score: 7
Explanation: The filing indicates an insider, August J. Troendle, is increasing his direct ownership in the company through option exercises, which generally signals confidence in the company's future performance. This is a positive signal for investors, although the filing itself is purely factual about ownership changes and does not contain financial performance data.
Positives
- August J. Troendle, a significant insider and reporting person, increasing his beneficial ownership through option exercises indicates confidence in Medpace Holdings, Inc.'s future prospects.
- The exercise of options, including a portion at a higher strike price of $107.93, suggests a belief in the stock's value above these levels.
Future Outlook
NA
Industry Context
This filing reflects an insider's increased stake in Medpace Holdings, Inc., a clinical research organization (CRO). In the broader biopharmaceutical services industry, insider confidence can be a positive signal, especially given the ongoing demand for outsourced clinical trials. While this filing doesn't provide industry-specific financial metrics, the actions of a key executive like August J. Troendle, who is likely deeply familiar with the company's operational performance and market position, can be interpreted as a positive indicator for Medpace's prospects within the competitive CRO landscape.
Stakeholder Impact
- Shareholders: The increase in insider ownership by August J. Troendle may be viewed positively, signaling management's confidence in the company's future and potentially aligning management interests more closely with shareholders.
Key Dates
| Date | Description |
|---|---|
| 2016-08-26 | Original Schedule 13D filed with the SEC. |
| 2018-08-08 | Amendment No. 1 to Schedule 13D filed. |
| 2018-10-02 | Amendment No. 2 to Schedule 13D filed. |
| 2019-02-06 | Amendment No. 3 to Schedule 13D filed. |
| 2019-08-05 | Amendment No. 4 to Schedule 13D filed. |
| 2019-08-07 | Amendment No. 5 to Schedule 13D filed. |
| 2019-08-15 | Amendment No. 6 to Schedule 13D filed. |
| 2019-09-17 | Amendment No. 7 to Schedule 13D filed. |
| 2020-05-08 | Amendment No. 8 to Schedule 13D filed. |
| 2020-07-31 | Amendment No. 9 to Schedule 13D filed. |
| 2020-08-14 | Amendment No. 10 to Schedule 13D filed. |
| 2020-12-21 | Amendment No. 11 to Schedule 13D filed. |
| 2021-04-21 | Amendment No. 12 to Schedule 13D filed. |
| 2021-09-01 | Amendment No. 13 to Schedule 13D filed. |
| 2021-12-23 | Amendment No. 14 to Schedule 13D filed. |
| 2022-07-06 | Amendment No. 15 to Schedule 13D filed. |
| 2022-09-13 | Amendment No. 16 to Schedule 13D filed. |
| 2022-09-21 | Amendment No. 17 to Schedule 13D filed. |
| 2023-09-22 | Amendment No. 18 to Schedule 13D filed. |
| 2023-12-05 | Amendment No. 19 to Schedule 13D filed. |
| 2024-02-28 | Amendment No. 20 to Schedule 13D filed. |
| 2024-03-08 | Amendment No. 21 to Schedule 13D filed. |
| 2025-03-06 | August J. Troendle granted 73,443 immediately vested options. |
| 2025-03-07 | August J. Troendle exercised 356,446 vested stock options. This is also the date of the event which requires this filing. |
| 2025-03-11 | Date of signing of this Amendment No. 22. |
Recommendation
holdKeywords
Medpace Holdings, MDCP, Schedule 13D, August J. Troendle, Medpace Investors LLC, Stock Options, Beneficial Ownership, Insider Trading, SEC Filing, Biopharmaceutical Services, Clinical Research Organization
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.